Skip to main content

Table 1 Baseline characteristics

From: Comparison of integrin αvβ3 expression with 68Ga-NODAGA-RGD PET/CT and glucose metabolism with 18F-FDG PET/CT in esophageal or gastroesophageal junction cancers

N

9

Age, y

58 ± 8.4

Men

8 (89%)

Body mass index (kg/m2)

29 ± 4.1

Tumor location at initial diagnosis—N (%)

Esophagus

8 (89%)

Gastroesophageal junction

1 (11%)

Histologic type—N (%)

Adenocarcinoma

6 (67%)

Squamous cell carcinoma

3 (33%)

Pathological lymph node status—N (%)

ypN0

1 (11%)

 ≥ ypN1

3 (33%)

pN0

3 (33%)

 ≥ pN1

0

Not known

2 (22%)

Pathological tumor status—N (%)

ypT0

1 (11%)

ypT1 or ypT2

0

ypT3 or ypT4

3 (33%)

pT0

0

pT1 or pT2

2 (22%)

pT3 or pT4

1 (11%)

Not known

2 (22%)

Histologic grade

1 or 2

8 (89%)

3 or 4

1 (11%)

Not assessed

0

Tumor-cell PD-L1 expression—N (%)

 < 1%

0

 ≥ 1%

2 (22%)

Indeterminate or could not be evaluated

7 (78%)

HER2 status

Positive

0

Negative

5 (56%)

Not reported

4 (44%)

ECOG performance-status score—N (%) *

0

6 (67%)

1

3 (33%)

  1. *ECOG performance-status scores range from 0 to 5, with higher scores indicating greater disability